Gilead Biktarvy tablets

Biktarvy is a high-profile prescription medication used in the management and treatment of HIV-1 infection. It is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide. The brand was developed and is owned by Gilead Sciences, an American biopharmaceutical company founded in 1987.

Manufacturing for Biktarvy occurs across a global supply chain, primarily involving high-tech facilities in the United States, Ireland, and Canada, though ingredients and packaging may involve other international sites. In Australia, the product is registered under the AUST R system and distributed through Gilead Sciences Pty Ltd, the local subsidiary. The brand remains under the ultimate ownership of the parent company, Gilead Sciences, Inc., based in California.